Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/1005
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorMARQUES, Ricardo Henrique-
dc.contributor.authorREIS, Fabiana G.-
dc.contributor.authorSTARLING, Claudia M.-
dc.contributor.authorCABIDO, Claudia-
dc.contributor.authorALMEIDA-REIS, Rafael de-
dc.contributor.authorDOHLNIKOFF, Marisa-
dc.contributor.authorPRADO, Carla M.-
dc.contributor.authorLEICK, Edna A.-
dc.contributor.authorMARTINS, Milton A.-
dc.contributor.authorTIBERIO, Iolanda F. L. C.-
dc.date.accessioned2013-07-30T15:15:06Z-
dc.date.available2013-07-30T15:15:06Z-
dc.date.issued2012-
dc.identifier.citationNEUROIMMUNOMODULATION, v.19, n.3, p.158-170, 2012-
dc.identifier.issn1021-7401-
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/1005-
dc.description.abstractMechanisms involved in stress-induced asthmatic alterations have been poorly characterised. We assessed whether inducible nitric oxide synthase (iNOS) inhibition modulates the stress-amplified lung parenchyma responsiveness, oxidative stress and extracellular matrix remodelling that was previously increased by chronic lung inflammation. Guinea pigs were subjected to 7 exposures to ovalbumin (1-5 mg/ml) or saline (OVA and SAL groups) over 4 weeks. To induce behavioural stress, animals were subjected to a forced swimming protocol (5 times/week, over 2 weeks; SAL-Stress and OVA-Stress groups) 24 h after the 4th inhalation. 1400W (iNOS-specific inhibitor) was administered intraperitoneally in the last 4 days of the protocol (SAL-1400W, OVA-1400W, SAL-Stress+1400W and OVA-Stress+1400W groups). Seventy-two hours after the last inhalation, animals were anaesthetised and exsanguinated, and adrenal glands were removed. Lung tissue resistance and elastance were evaluated by oscillatory mechanics and submitted for histopathological evaluation. Stressed animals had higher adrenal weights compared to non-stressed groups, which were reduced by 1400W treatment. Behavioural stress in sensitised animals amplified the resistance and elastance responses after antigen challenge, numbers of eosinophils and iNOS+ cells, actin content and 8-iso-PGF2 alpha density in the distal lung compared to the OVA group. 1400W treatment in ovalbumin-exposed and stressed animals reduced lung mechanics, iNOS+ cell numbers and 8-iso-PGF2a density compared to sensitised and stressed animals that received vehicle treatment. We concluded that stress amplifies the distal lung constriction, eosinophilic inflammation, iNOS expression, actin content and oxidative stress previously induced by chronic lung inflammation. iNOS-derived NO contributes to stress-augmented lung tissue functional alterations in this animal model and is at least partially due to activation of the oxidative stress pathway.-
dc.language.isoeng-
dc.publisherKARGER-
dc.relation.ispartofNeuroimmunomodulation-
dc.rightsrestrictedAccess-
dc.subjectExperimental asthma model-
dc.subjectBehavioural stress-
dc.subjectLung parenchyma-
dc.subjectInducible nitric oxide synthase-
dc.subjectOxidative stress-
dc.subject.otherallergic airway inflammation-
dc.subject.othercorticotropin-releasing hormone-
dc.subject.otherforced swim test-
dc.subject.otherextracellular-matrix-
dc.subject.otherguinea-pigs-
dc.subject.otherexperimental-model-
dc.subject.othertissue mechanics-
dc.subject.othersensitized rats-
dc.subject.otherin-vitro-
dc.subject.otherpsychological stress-
dc.titleInducible Nitric Oxide Synthase Inhibition Attenuates Physical Stress-Induced Lung Hyper-Responsiveness and Oxidative Stress in Animals with Lung Inflammation-
dc.typearticle-
dc.rights.holderCopyright KARGER-
dc.identifier.doi10.1159/000331264-
dc.identifier.pmid22262048-
dc.subject.wosEndocrinology & Metabolism-
dc.subject.wosImmunology-
dc.subject.wosNeurosciences-
dc.type.categoryoriginal article-
dc.type.versionpublishedVersion-
hcfmusp.description.beginpage158-
hcfmusp.description.endpage170-
hcfmusp.description.issue3-
hcfmusp.description.volume19-
hcfmusp.origemWOS-
hcfmusp.origem.idWOS:000301330800005-
hcfmusp.origem.id2-s2.0-84855895539-
hcfmusp.publisher.cityBASEL-
hcfmusp.publisher.countrySWITZERLAND-
hcfmusp.relation.referenceAlmeida-Reis R, 2010, RESP PHYSIOL NEUROBI, V173, P79, DOI 10.1016/j.resp.2010.06.011-
hcfmusp.relation.referenceAngeli P, 2008, AM J PHYSIOL-LUNG C, V294, pL1197, DOI 10.1152/ajplung.00199.2007-
hcfmusp.relation.referenceAraujo BB, 2008, EUR RESPIR J, V32, P61, DOI 10.1183/09031936.00147807-
hcfmusp.relation.referenceBLACK PH, 1994, ANTIMICROB AGENTS CH, V38, P1-
hcfmusp.relation.referenceBOULET LP, 1995, AM J RESP CRIT CARE, V152, P865-
hcfmusp.relation.referenceBousquet J, 2000, AM J RESP CRIT CARE, V161, P1720-
hcfmusp.relation.referenceBriest W, 2003, CARDIOVASC RES, V57, P379, DOI 10.1016/S0008-6363(02)00700-9-
hcfmusp.relation.referenceCapelozzi MA, 2007, RESP PHYSIOL NEUROBI, V156, P171, DOI 10.1016/j.resp.2006.09.004-
hcfmusp.relation.referenceChakir J, 2003, J ALLERGY CLIN IMMUN, V111, P1293, DOI 10.1067/mai.2003.1557-
hcfmusp.relation.referenceChen E, 2007, BRAIN BEHAV IMMUN, V21, P993, DOI 10.1016/j.bbi.2007.03.009-
hcfmusp.relation.referenceChi DS, 2003, NITRIC OXIDE-BIOL CH, V8, P127, DOI 10.1016/S1089-8603(02)00148-9-
hcfmusp.relation.referenceChida Y, 2007, AM J RESP CRIT CARE, V175, P316, DOI 10.1164/rccm.200607-898OC-
hcfmusp.relation.referenceContreras CM, 2001, J PSYCHOPHARMACOL, V15, P231-
hcfmusp.relation.referenceCryan JF, 2000, EUR J PHARMACOL, V409, P295, DOI 10.1016/S0014-2999(00)00858-X-
hcfmusp.relation.referenceDolhnikoff M, 1998, AM J RESP CRIT CARE, V158, P1607-
hcfmusp.relation.referenceDolhnikoff M, 1999, AM J RESP CRIT CARE, V160, P1750-
hcfmusp.relation.referenceElenkov I. J., 1999, ANN NY ACAD SCI, V876, P11-
hcfmusp.relation.referenceElenkov IJ, 1999, ANN NY ACAD SCI, V876, P1, DOI 10.1111/j.1749-6632.1999.tb07618.x-
hcfmusp.relation.referenceForsythe P, 2004, AM J RESP CRIT CARE, V169, P220, DOI 10.1164/rccm.200307-979OC-
hcfmusp.relation.referenceGarvey EP, 1997, J BIOL CHEM, V272, P4959-
hcfmusp.relation.referenceGrange-Messent V, 2004, J NEUROSCI RES, V78, P683, DOI 10.1002/jnr.20331-
hcfmusp.relation.referenceHoglund CO, 2006, CLIN EXP ALLERGY, V36, P982, DOI 10.1111/j.1365-2222.2006.02529.x-
hcfmusp.relation.referenceHolgate S. T., 2001, Clinical and Experimental Allergy Reviews, V1, P59, DOI 10.1046/j.1472-9725.2001.00006.x-
hcfmusp.relation.referenceJang S, 2008, NEUROCHEM RES, V33, P842, DOI 10.1007/s11064-007-9523-6-
hcfmusp.relation.referenceJanssen LJ, 2001, AM J PHYSIOL-LUNG C, V280, pL1067-
hcfmusp.relation.referenceLancas T, 2006, J APPL PHYSIOL, V100, P1610, DOI 10.1152/japplphysiol.00828.2005-
hcfmusp.relation.referenceLAUZON AM, 1991, J APPL PHYSIOL, V71, P1159-
hcfmusp.relation.referenceLeick-maldonado EA, 2004, CLIN EXP ALLERGY, V34, P145, DOI 10.1111/j.1365-2222.2004.01854.x-
hcfmusp.relation.referenceLiu LY, 2002, AM J RESP CRIT CARE, V165, P1062, DOI 10.1164/rccm.2109065-
hcfmusp.relation.referenceLuna L. G, 1968, MANUAL HIST STAINING-
hcfmusp.relation.referenceMachida K, 2005, AM J PHYSIOL-LUNG C, V288, pL860, DOI 10.1152/ajplung.00131.2004-
hcfmusp.relation.referenceMarshall GD, 2000, ALLERGY ASTHMA PROC, V21, P241, DOI 10.2500/108854100778248917-
hcfmusp.relation.referenceMauad T, 2004, AM J RESP CRIT CARE, V170, P857, DOI 10.1164/rccm.200403-305OC-
hcfmusp.relation.referenceMeurs H, 2000, BRIT J PHARMACOL, V130, P1793, DOI 10.1038/sj.bjp.0703488-
hcfmusp.relation.referenceMiller GE, 2002, HEALTH PSYCHOL, V21, P531, DOI 10.1037//0278-6133.21.6.531-
hcfmusp.relation.referenceMiller M, 2006, AM J PHYSIOL-LUNG C, V290, pL162, DOI 10.1152/ajplung.00252.2005-
hcfmusp.relation.referenceMontuschi P, 1999, AM J RESP CRIT CARE, V160, P216-
hcfmusp.relation.referenceMuijsers RBM, 1997, LIFE SCI, V60, P1833, DOI 10.1016/S0024-3205(96)00651-0-
hcfmusp.relation.referenceNAGASE T, 1995, AM J RESP CRIT CARE, V152, P81-
hcfmusp.relation.referenceNakashima AS, 2008, J APPL PHYSIOL, V104, P1778, DOI 10.1152/japplphysiol.00830.2007-
hcfmusp.relation.referenceNittoh T, 1998, EUR J PHARMACOL, V354, P73, DOI 10.1016/S0014-2999(98)00426-9-
hcfmusp.relation.referencePORSOLT RD, 1979, BIOMEDICINE, V30, P139-
hcfmusp.relation.referencePortela CD, 2002, AM J PHYSIOL-LUNG C, V282, pL1289, DOI 10.1152/ajplung.00352.2001-
hcfmusp.relation.referencePortela CP, 2007, NEUROIMMUNOMODULAT, V14, P105, DOI 10.1159/000107765-
hcfmusp.relation.referencePrado CM, 2005, AM J PHYSIOL-LUNG C, V288, pL741, DOI 10.1152/ajplung.00208.2004-
hcfmusp.relation.referencePrado CM, 2005, AM J PHYSIOL-LUNG C, V289, pL677, DOI 10.1152/ajplung.00010.2005-
hcfmusp.relation.referencePrado CM, 2006, AM J RESP CELL MOL, V35, P457, DOI 10.1165/rcmb.2005-0391OC-
hcfmusp.relation.referencePRYOR WA, 1995, AM J PHYSIOL-LUNG C, V268, pL699-
hcfmusp.relation.referenceRenard CE, 2001, PSYCHOPHARMACOLOGY, V159, P42, DOI 10.1007/s002130100836-
hcfmusp.relation.referenceRicciardolo FLM, 2003, THORAX, V58, P175, DOI 10.1136/thorax.58.2.175-
hcfmusp.relation.referenceRitz T, 2000, PSYCHOSOM MED, V62, P808-
hcfmusp.relation.referenceRitz T, 2000, PSYCHOSOM MED, V62, P401-
hcfmusp.relation.referenceRocco PRM, 2001, AM J RESP CRIT CARE, V164, P1067-
hcfmusp.relation.referenceSivonova M, 2004, STRESS, V7, P183, DOI 10.1080/10253890400012685-
hcfmusp.relation.referenceStarling CM, 2009, RESP PHYSIOL NEUROBI, V165, P185, DOI 10.1016/j.resp.2008.11.011-
hcfmusp.relation.referenceTiberio Iolanda F. L. C., 2003, Experimental Lung Research, V29, P165, DOI 10.1080/01902140303772-
hcfmusp.relation.referenceTorres RL, 2004, BRAZ J MED BIOL RES, V37, P185-
hcfmusp.relation.referenceUmetsu DT, 2006, CURR OPIN IMMUNOL, V18, P727, DOI 10.1016/j.coi.2006.09.007-
hcfmusp.relation.referenceVig RS, 2006, ANN NY ACAD SCI, V1088, P65, DOI 10.1196/annals.1366.023-
hcfmusp.relation.referenceWatanabe T, 2004, AM J RESP CRIT CARE, V169, P105, DOI 10.1164/rccm.200302-2390C-
hcfmusp.relation.referenceWebster EL, 1998, ANN NY ACAD SCI, V840, P21, DOI 10.1111/j.1749-6632.1998.tb09545.x-
hcfmusp.relation.referenceWright RJ, 1998, THORAX, V53, P1066-
hcfmusp.relation.referenceWright RJ, 2005, CURR OPIN ALLERGY CL, V5, P23, DOI 10.1097/00130832-200502000-00006-
hcfmusp.relation.referenceXisto DG, 2005, AM J RESP CRIT CARE, V171, P829, DOI 10.1164/rccm.200408-997OC-
hcfmusp.relation.referenceYang EV, 2006, CANCER RES, V66, P10357, DOI 10.1158/0008-5472.CAN-06-2496-
hcfmusp.relation.referenceZivkovic IP, 2005, J NEUROIMMUNOL, V160, P77, DOI 10.1016/j.jneuroim.2004.11.002-
dc.description.indexMEDLINE-
hcfmusp.lim.ref2012-
hcfmusp.citation.scopus10-
hcfmusp.scopus.lastupdate2022-05-06-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MCM
Departamento de Clínica Médica - FM/MCM

Artigos e Materiais de Revistas Científicas - FM/MPT
Departamento de Patologia - FM/MPT

Artigos e Materiais de Revistas Científicas - HC/ICHC
Instituto Central - HC/ICHC

Artigos e Materiais de Revistas Científicas - HC/ICr
Instituto da Criança - HC/ICr

Artigos e Materiais de Revistas Científicas - HC/InCor
Instituto do Coração - HC/InCor

Artigos e Materiais de Revistas Científicas - LIM/05
LIM/05 - Laboratório de Poluição Atmosférica Experimental

Artigos e Materiais de Revistas Científicas - LIM/20
LIM/20 - Laboratório de Terapêutica Experimental


Files in This Item:
File Description SizeFormat 
art_MARQUES_Inducible_Nitric_Oxide_Synthase_Inhibition_Attenuates_Physical_Stress_2012.PDF
  Restricted Access
publishedVersion (English)1.54 MBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.